Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Share News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.20
Bid: 3.10
Ask: 3.30
Change: -0.80 (-20.00%)
Spread: 0.20 (6.452%)
Open: 4.15
High: 4.35
Low: 3.15
Prev. Close: 4.00
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK EXECUTIVE CHANGE SUMMARY: Immedia Picks COO Penney As Interim CEO

Fri, 01st May 2020 14:57

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Friday and not separately reported by Alliance News:

----------

Immedia Group PLC - multi-media content - Chief Operating Officer Ross Penney named interim chief executive, with immediate effect. Bruno Brookes steps down as CEO "to focus on his other interests". Penney joined Immedia in 2006 as part of its acquisition of Cube Music.

----------

Orosur Mining Inc - South American-focused gold developer - hires Brad George as non-executive director. George is a Perth, Australia-based geoscientist with experience in South America and West Africa.

----------

ValiRx PLC - clinical stage biotechnology - Plans to appoint Suzanne Dilly as a director. Dilly has been chief executive officer of subsidiary ValiSeek Ltd since 2014.

----------

Horizon Discovery Group PLC - gene editing and modulation - Hires Siddhartha Kadia as non-executive director, replacing Susan Galbraith, effective Thursday. Kadia was CEO of EAG Laboratories until its acquisition by Eurofins Scientific in 2017. Galbraith currently is head of Early Oncology at AstraZeneca PLC, leaving Horizon Discovery due to increased responsibilities there, Horizon said.

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
1 Apr 2020 12:12

ValiRx Raises GBP200,000 To Improve "Extremely Weak" Capital Position

ValiRx Raises GBP200,000 To Improve "Extremely Weak" Capital Position

Read more
30 Mar 2020 16:41

ValiRx "Critically Short" Of Working Capital, In Funding Discussions

ValiRx "Critically Short" Of Working Capital, In Funding Discussions

Read more
10 Mar 2020 11:42

ValiRx Still Faces Going Out Of Business; Proposes New Share Plan

ValiRx Still Faces Going Out Of Business; Proposes New Share Plan

Read more
4 Mar 2020 17:25

ValiRx Investors Seek Removal Of Directors Morris And Vainikka

ValiRx Investors Seek Removal Of Directors Morris And Vainikka

Read more
17 Feb 2020 12:48

ValiRx's Future In Doubt As Investors Say No To Capital Reogranisation

ValiRx's Future In Doubt As Investors Say No To Capital Reogranisation

Read more
10 Feb 2020 16:00

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
14 Jan 2020 14:50

ValiRx signs letter of intent in a bid to fund VAL401

(Sharecast News) - Clinical-stage biotechnology company ValiRx updated the market on its subsidiary joint venture, ValiSeek, and its cancer therapeutic, VAL401 on Tuesday.

Read more
14 Jan 2020 11:08

ValiRx Joint Venture Partner Enters Agreement For VAL401 Funding

ValiRx Joint Venture Partner Enters Agreement For VAL401 Funding

Read more
6 Jan 2020 09:59

ValiRx Raises GBP200,000 To Progress Product Development

ValiRx Raises GBP200,000 To Progress Product Development

Read more
16 Dec 2019 10:17

ValiRx Reveals "Clear Impact" Of VAL201 On Prostate Cancer Patients

ValiRx Reveals "Clear Impact" Of VAL201 On Prostate Cancer Patients

Read more
28 Nov 2019 16:13

ValiRx granted US patent for 'VAL201' compound

(Sharecast News) - Clinical stage biotechnology company ValiRx announced on Thursday that the US Patent and Trademark Office has granted patent number 10,400,008, titled 'Modulators Of The SRC-Kinase Activity For Preventing Or Treating Metastatic Cancer', to its lead therapeutic compound 'VAL201'.

Read more
28 Nov 2019 15:57

ValiRx Granted "Key" US Patent Protection For VAL201 Cancer Treatment

ValiRx Granted "Key" US Patent Protection For VAL201 Cancer Treatment

Read more
14 Oct 2019 13:44

ValiRx Raises GBP350,000 Through Placing To Progress Clinical Trials

ValiRx Raises GBP350,000 Through Placing To Progress Clinical Trials

Read more
26 Sep 2019 11:43

ValiRx Reports Narrowed Loss In First Half As Expenses Reduce

ValiRx Reports Narrowed Loss In First Half As Expenses Reduce

Read more
24 Sep 2019 12:40

ValiRx Receives GBP423,000 Research & Development Credit From UK HMRC

ValiRx Receives GBP423,000 Research & Development Credit From UK HMRC

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.